10results about How to "Inhibit progress" patented technology

The invention belongs to the technical field of traditional Chinese medicine, and particularly discloses a traditional Chinese medicine composition for treating fibromyalgia syndrome and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from radix polygoni multiflori preparata, fructus citri sarcodactylis, radix pseudostellariae, caulis spatholobi, flos rosae rugosae, rhizoma dioscoreae, semen lablab album, rhizoma curcumae longae, lucid ganoderma, arillus longan, flos albiziae and fructus ziziphi jujubae. The traditional Chinese medicine has the effects of soothing liver and strengthening spleen, nourishing and activating blood, calming heart and tranquilizing mind, and activating meridians Pharmacodynamic experiment research and clinical observation results show that the traditional Chinese medicine composition can significantly relieve pain of patients and improve depressive symptoms, and can be used for treating fibromyalgia syndrome.

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

Provided are a composition for treatment and the like of bovine papillomatosis caused by bovine papillomavirus, and a method using the same. Provided are a composition for treatment, amelioration, and / or suppressing the progression of bovine papillomatosis caused by bovine papillomavirus, the composition containing, as an active ingredient, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound; and a method for treating, ameliorating, and / or suppressing progression of, bovine papillomatosis caused by bovine papillomavirus, the method including administering, to a cow, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound:

The invention discloses an application of paclitaxel in preparation of an anti-breast cancer drug. The invention proposes and verifies that taxafen effectively down-regulates WDYHV1 protein expression of tamoxifen drug-resistant breast cancer cells and induces ferroptosis of cancer cells for the first time, so that the activity of tamoxifen drug-resistant tumor cells is remarkably reduced, the development of breast cancer is inhibited, and a new direction is provided for treatment of tamoxifen drug-resistant lung cancer.

This invention belongs to the field of novel carbon nanomaterials technology, and discloses a Clostridium butyricum-derived carbon dot boat-shaped nanoparticle, its preparation method, and its application. The preparation method includes the following steps: Step 1, Clostridium butyricum is cultured to the logarithmic growth phase, and then placed in a pretreatment solution for suspension incubation to regulate the structural integrity and surface chemical composition of Clostridium butyricum cells. The pretreatment solution is an aqueous solution of EDTA, NaCl, or PEG-8000. After incubation, the precipitate is collected by centrifugation, washed, and resuspended in ultrapure water; Step 2, the Clostridium butyricum treated in Step 1 is placed in a high-pressure reactor for hydrothermal reaction to obtain a crude product system; Step 3, the crude product system is filtered and purified, and freeze-dried to obtain Clostridium butyricum-derived carbon dot boat-shaped nanoparticles. The nanoparticles prepared by this invention have uniform particle size, good water solubility, dispersibility, and biocompatibility, and exhibit significant immunomodulatory functions.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an mTOR inhibitor to improvement of sleep disorders. Aiming at the defects of the existing hypnotics, the invention finds that the sleep disorder can be improved by using the Rapamycin through researching a new sleep pathway target. The Rapamycin disclosed by the invention is a non-addictive sleeping drug, and can induce natural sleep behaviors; compared with an existing clinical hypnotics which has the side effect of greatly increasing the death rate, the Rapamycin administration disclosed by the invention is beneficial to improving the sleep quality and prolonging the life of animals at the same time. The invention discloses a remarkable effect of Rapamycin in the aspect of improving the sleep disorder, and the discovery has important significance in improving the sleep quality of a patient and preventing the progress of diseases, so that the Rapamycin has a wide medical prospect and a remarkable economic value.

A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

The invention discloses application of a PDLIM2 gene overexpression virus vector in preparation of a medicine for treating podocytosis. The nucleotide sequence of a PDLIM2 gene is as shown in SEQ ID NO: 1. The core effect of the PDLIM2 gene in podocytosis protection is found and verified for the first time, it is confirmed that the expression of the PDLIM2 gene in DKD and FSGS disease models is remarkably reduced, and functional experiments prove that the overexpression of the PDLIM2 can effectively stabilize podocytoskeleton, inhibit apoptosis and relieve proteinuria, so that the PDLIM2 gene is determined as a key target gene for treating podocytosis. According to the invention, the stability of the cytoskeleton, which is a core link of podocyte injury, is intervened from the gene level for the first time. The expression of the PDLIM2 in the podocyte is specifically up-regulated, so that the internal cytoskeleton support and damage resistance of the podocyte are directly enhanced, and the fundamental treatment strategy conversion from symptomatic support to cause repair is realized.

This invention discloses the application of the compound pimozide in combination with metronidazole in the preparation of a drug for improving oocyte quality and treating endometriosis-related fertility disorders, belonging to the field of biomedical technology. The efficacy of this invention was verified by constructing mouse models of endometriosis driven by pathogenic *Prevotella bisporus* and mouse models of ovarian endometriosis. Experimental results showed that the combined administration significantly eliminated *Prevotella bisporus* colonizing ectopic lesions, reduced succinic acid content in both eutopic and ectopic lesions, decreased the succinylation level of lysine residue 195 of the ACADVL protein, reduced the fluidity of primary endometrial epithelial cell membranes, reduced the volume and weight of endometriotic lesions, and improved oocyte spermatogenesis, ovulation rate, and litter size. This invention solves the problem that existing therapies cannot simultaneously control endometriosis lesions and protect reproductive function, providing a new, safe, and effective combined treatment option for patients with endometriosis and infertility.

The present application relates to the technical field of biological medicine, disclose a kind of new use of human-derived miR-335-3p and the method for regulating target gene IL-16 expression, its new use is to inhibit yellow ligament cell fibrosis, and hsa-miR-335-3p can be targeted to bind IL-16 mRNA 3'UTR, the 8mer binding site of human-derived miR-335-3p and IL-16 mRNA 3'UTR exists, located at 775-782 of 3'UTR, to inhibit the expression of IL-16 gene, and interfere with the function of IL-16 gene to promote yellow ligament hypertrophy, it has wide application prospect on the drug related to lumbar yellow ligament hypertrophy, based on the present application can be made to treat or prevent the disease related to lumbar yellow ligament hypertrophy drug or detection kit.